Table 2.
Recent Studies of Platelets in Murine Models of Acute Lung Injury
Model | Major Platelet Activities Examined and/or Variables Influenced by Platelets | Reference |
---|---|---|
LPS-induced ALI (aerosolized) | Lung neutrophil accumulation, increased alveolar–capillary permeability | 66 |
LPS-induced ALI (intranasal) | Alveolar–capillary barrier function, inflammation-induced alveolar hemorrhage | 77 |
LPS-induced ALI (intratracheal) | Intraalveolar platelet sequestration, platelet–neutrophil aggregate formation, increased alveolar–capillary permeability | 43 |
LPS-induced ALI (intranasal) | Leukocyte recruitment to the lungs | 36-38 |
LPS-induced ALI (aerosolized) | Neutrophil recruitment to lungs, increased alveolar–capillary permeability | 170 |
LPS-induced ALI (intranasal) | Inflammation-induced alveolar hemorrhage | 81 |
Klebsiella pneumoniae pneumonia, “pneumosepsis” | Bacterial burden in lungs, blood, systemic organs; inflammation-induced alveolar hemorrhage; leukocyte recruitment to lungs; NET formation; endothelial activation; cytokine concentrations; coagulation | 76, 115 |
Streptococcus pneumoniae pneumonia | Bacterial burden in lungs, blood, spleen; cytokine concentrations; coagulation | 102 |
Escherichia coli pneumonia | Platelet–leukocyte interaction, neutrophil recruitment to lungs, transcellular metabolism, platelet-endothelial signaling | 39 |
H7N7 influenza A | Platelet accumulation in alveolar compartments, platelet–leukocyte interaction, platelet activation markers in BAL fluid, natural history of infection | 104 |
H1N1 influenza A | Activation of platelets by influenza virus | 106 |
CLP | Lung neutrophil accumulation, increased alveolar–capillary permeability | 66 |
CLP | Lung neutrophil accumulation, lung edema, alveolar inflammation by histologic score | 117 |
CLP | Lung neutrophil accumulation, lung edema, alveolar inflammation by histologic score | 118 |
Acid-induced ALI | Increased alveolar–capillary permeability | 32 |
Acid-induced ALI | Lung neutrophil accumulation, increased alveolar–capillary permeability | 66 |
Acid-induced ALI | Lung endothelial cell activation, development of procoagulant lung endothelium | 133 |
Acid-induced ALI | Platelet–neutrophil aggregation, alterations in lung barrier integrity induced by intravascular platelet–neutrophil interactions | 132 |
Acid-induced ALI | Alveolar neutrophil accumulation, increased alveolar–capillary permeability, alveolar inflammation by histologic score | 65 |
TRALI | Platelet sequestration in lungs, platelet–neutrophil interaction, increased alveolar–capillary permeability | 32 |
TRALI | Platelet sequestration in lungs, NET formation, increased alveolar–capillary permeability | 58 |
TRALI | Platelet–neutrophil interaction, increased alveolar–capillary permeability | 43 |
TRALI | Neutrophil–platelet interaction, NET formation, pulmonary edema | 33 |
TRALI | Platelets not required for increased alveolar–capillary permeability and decreased oxygenation but influenced alveolar hemorrhage in this study | 142 |
VILI | Oxygenation, lung neutrophil accumulation, increased alveolar–capillary permeability | 60 |
Definition of abbreviations: ALI = acute lung injury; CLP = cecal ligation and puncture; NET = neutrophil extracellular trap; TRALI = transfusion-related ALI; VILI = ventilator-induced lung injury.
The list of studies of platelets in experimental models of ALI in this table is not comprehensive, and other relevant investigations using animal models are mentioned in the text. Major variables and platelet activities examined in the studies are indicated, but many of the individual reports contain additional useful findings (e.g., effect on survival). In the listed studies, approaches to indicate contributions by platelets included induced or genetic thrombocytopenia, genetic alterations in platelet adhesion or signaling molecules, inhibition of platelet mediators, and/or administration of antiplatelet drugs or aspirin-triggered lipoxins. Earlier studies of platelets in experimental animal models are mentioned in the text and reviewed in References 12 and 14.